Mary Homer

Mary Homer serves as a key procurement professional within the ASPR BARDA Division of Contracts Management and Acquisition, supporting the Department of Health and Human Services in advancing national biomedical preparedness. She manages the acquisition lifecycle for critical medical countermeasures, including vaccines, therapeutics, diagnostics, and personal protective equipment, ensuring rapid development and scalable production in response to public health emergencies. Her work directly enables the agency’s mission to safeguard the nation against biological, chemical, radiological, and nuclear threats through timely, compliant, and mission-driven contracting. She routinely handles complex, high-priority procurements under FAR Part 35 and Other Transaction Authority (OTA) mechanisms, often involving accelerated timelines and multi-phase development contracts. Mary collaborates with a diverse range of contractors, including large biopharmaceutical manufacturers, advanced technology developers, and specialized contract research organizations. Her procurement patterns reflect a preference for established industry partners with proven capabilities in GMP manufacturing, clinical trial support, and regulatory pathway navigation. While no single vendor dominates her portfolio, she consistently engages firms with prior experience in BARDA-funded programs and demonstrated agility in meeting urgent federal health security needs. Her contracting approach reflects a strong emphasis on full and open competition, with 100% of her acquisitions conducted without set-asides. This reflects the mission-critical nature of the procurements, where speed, scale, and technical readiness take precedence over socioeconomic preferences. While small business participation is not formally prioritized in her portfolio, she remains aligned with federal goals by ensuring fair access to opportunities where capabilities permit. Mary’s expertise centers on NAICS categories related to pharmaceutical and medicine manufacturing, clinical research services, and medical device development. She specializes in procuring advanced biologics, novel antivirals, point-of-care diagnostics, and countermeasure delivery systems, requiring deep familiarity with FDA regulatory frameworks, biosafety standards, and supply chain resilience requirements.